Top story
Samsung Biologics Wage Impasse Lingers After Electronics' 12% Profit-Share Reset
Samsung Biologics (KRX: 207940), Korea's largest contract drug manufacturer (CDMO), has not yet matched the wage settlement its memory-chip affiliate concluded
- 02
Nomura: KOSPI 11,000; ₩1.94T Flows Into Samsung, SK Hynix
- 03
Samsung (005930.KS) Averts Strike; Treasury Deal Sparks Lawsuit
- 04
Samsung SDS (018260.KS) Q1 2026: Op Profit Plunges 71% on 18x DOL
- 05
Celltrion (068270.KS) Adds ₩200B to 2026 Buyback as 0.05 Bonus Issue Sets June Listing
Celltrion added a ₩100B treasury buyback plus a ₩100B parent purchase on May 21, lifting 2026 cancellations toward ~₩2T as a 0.05 bonus issue lists 10.92M shares.
LineVest Daily
Get this wrap in your inbox every morning.
One email before the U.S. open — the earnings, filings, and guidance changes that matter, in plain English. Free.
Subscribe free